Autolus Therapeutics (AUTL, Financial) reported a remarkable first-quarter revenue of $8.982 million, significantly surpassing the market's expected $1.98 million. This impressive start reflects growing physician support for AUCATZYL in the United States, highlighting both the product's promising profile and the existing demand for novel treatments. CEO Dr. Christian Itin expressed optimism about this achievement and noted the company's progress in expanding its market reach.
Following its success in the U.S., Autolus recently received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The company is actively working with the National Institute for Health and Care Excellence to make AUCATZYL available to patients in the UK. Autolus' strategic expansion plans are supported by its robust proprietary manufacturing and commercial infrastructure, setting the stage for further growth and execution in new markets.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Autolus Therapeutics PLC (AUTL, Financial) is $9.81 with a high estimate of $14.00 and a low estimate of $6.00. The average target implies an upside of 697.56% from the current price of $1.23. More detailed estimate data can be found on the Autolus Therapeutics PLC (AUTL) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Autolus Therapeutics PLC's (AUTL, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Autolus Therapeutics PLC (AUTL, Financial) in one year is $4.88, suggesting a upside of 296.75% from the current price of $1.23. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Autolus Therapeutics PLC (AUTL) Summary page.
AUTL Key Business Developments
Release Date: March 20, 2025
- Cash Equivalents and Marketable Securities: $588 million at year-end 2024, up from $239 million at December 31, 2023.
- Loss from Operations: $241.4 million for the year ending December 31, 2024, compared to $179.7 million in 2023.
- Cost of Sales: $11.4 million following BLA approval for obe-cel.
- Research and Development Expenses: $138.4 million for the year ending December 31, 2024, up from $130.5 million in 2023.
- Selling, General and Administrative Expenses: $101.1 million for the year, up from $46.7 million in 2023.
- Net Loss: $220.7 million for the year ending December 31, 2024, compared to $208.4 million in 2023.
- Milestone Payments: $30 million received from Blackstone; GBP10 million regulatory milestone payment made under UCLB license agreement.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Autolus Therapeutics PLC (AUTL, Financial) successfully launched AUCATZYL in the US, achieving FDA approval ahead of schedule without requiring a REMS program.
- The company added $600 million to its balance sheet through a collaboration with BioNTech and public financing, strengthening its financial position.
- Clinical results for obe-cel were published in the New England Journal of Medicine, and the product was included in the NCCN guidelines, supporting its credibility and adoption.
- Autolus Therapeutics PLC (AUTL) has authorized 33 centers to deliver AUCATZYL, covering approximately 60% of the target patient population in the US.
- The company is progressing with regulatory steps in the UK and Europe, expecting decisions in the second half of 2025, and is preparing for an R&D event to outline future growth opportunities.
Negative Points
- Loss from operations increased to $241.4 million in 2024 from $179.7 million in 2023, indicating rising operational costs.
- Research and development expenses rose to $138.4 million, driven by increased salaries and manufacturing costs, impacting profitability.
- Selling, general, and administrative expenses more than doubled to $101.1 million, reflecting higher costs associated with commercialization activities.
- Net loss for 2024 was $220.7 million, up from $208.4 million in 2023, highlighting ongoing financial challenges.
- The company has not provided sales guidance for AUCATZYL, creating uncertainty about future revenue projections.
